Jul. 2 at 1:46 PM
$SLDB Top-tier healthcare funds like Bain Capital, RA Capital, and Perceptive Advisors dominate the ownership structure of Solid Biosciences (
$SLDB) for very specific, data-driven reasons.
Right now, these institutions collectively control massive stakes: Perceptive holds over 12%, RA Capital holds nearly 12%, and Bain Capital commands roughly 10% of the company. The short, data-filled reality of why they have concentrated hundreds of millions of dollars into this asset comes down to three main pillars:
1. Anchoring the
$240M Capital FortressThese funds didn't just buy shares on the open market; they completely anchored the oversubscribed
$240 million private placement in March. They aggressively bought in at
$5.61 per share (and
$5.609 per pre-funded warrant). By doing this, they didn't just bet on the pipeline—they actively funded it, combining that fresh capital with Solid's existing cash to build a fortified corporate war chest of roughly
$414 million.
